Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
30actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-31 | actual | When the study began enrolling |
| Primary completion | 2026-02-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-19 | actual | The whole study's end, after follow-up |
| First posted | 2025-11-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: Repotrectinib
- Drug: Metformin
- Drug: Digoxin
- Drug: Rosuvastatin
- Drug: Bupropion
- Drug: Flurbiprofen
- Drug: Omeprazole
Primary outcomes
what the primary-completion date above is the date OFCohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of AUC (0-T) of Probe Substrate With Repotrectinib
measured Up to approximately Day 17 post dose
Cohort 1: AUC (0-T) of Probe Substrate Without Repotrectinib
measured Up to approximately Day 17 post dose
Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Probe Substrate With Repotrectinib
measured Up to approximately Day 17 post dose
Cohort 1: AUC(INF) of Probe Substrate Without Repotrectinib
measured Up to approximately Day 17 post dose
Cohort 1: Maximum Observed Plasma Concentration (Cmax) of Probe Substrate With Repotrectinib
measured Up to approximately Day 17 post dose
Cohort 1: Cmax of Probe Substrate Without Repotrectinib
measured Up to approximately Day 17 post dose
Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to 48 Hours Post Dose (AUC (0-48)) of Metformin With Repotrectinib
measured Up to approximately Day 17 post dose
Cohort 1: AUC (0-48) of Metformin Without Repotrectinib
measured Up to approximately Day 17 post dose
Cohort 1: Renal Clearance (CLR) of Metformin in Urine
measured Up to approximately Day 16 post dose
Cohort 2: AUC (0-T) of Probe Substrate With Repotrectinib
measured Up to approximately Day 17 post dose
Cohort 2: AUC (0-T) of Probe Substrate Without Repotrectinib
measured Up to approximately Day 17 post dose
Cohort 2: AUC (INF) of Probe Substrate With Repotrectinib
measured Up to approximately Day 17 post dose
Cohort 2: AUC (INF) of Probe Substrate Without Repotrectinib
measured Up to approximately Day 17 post dose
Cohort 2: Cmax of Probe Substrate With Repotrectinib
measured Up to approximately Day 17 post dose
Cohort 2: Cmax of Probe Substrate Without Repotrectinib
measured Up to approximately Day 17 post dose
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed